All-trans-retinoic acid modulation of drug-metabolizing enzyme activities: investigation with selective metabolic drug probes

[1]  R. Frye,et al.  Validation of the five‐drug “Pittsburgh cocktail” approach for assessment of selective regulation of drug‐metabolizing enzymes , 1997, Clinical pharmacology and therapeutics.

[2]  R. Branch,et al.  Improved high-performance liquid chromatographic determination of debrisoquine and 4-hydroxydebrisoquine in human urine following direct injection. , 1996, Journal of chromatography. B, Biomedical applications.

[3]  M. Relling,et al.  Nomenclature for N-acetyltransferases. , 1995, Pharmacogenetics.

[4]  U. Fuhr,et al.  Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. , 1994, Pharmacogenetics.

[5]  M. Kris,et al.  Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. , 1993, Journal of the National Cancer Institute.

[6]  M. Andreeff,et al.  Induction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all-trans-retinoic acid. , 1993, Cancer research.

[7]  C. Young,et al.  Lipid hydroperoxides greatly increase the rate of oxidative catabolism of all-trans-retinoic acid by human cell culture microsomes genetically enriched in specified cytochrome P-450 isoforms. , 1993, Cancer research.

[8]  R. Branch,et al.  Sensitive high-performance liquid chromatographic determination of chlorzoxazone and 6-hydroxychlorzoxazone in plasma. , 1993, Journal of chromatography.

[9]  R. Hoover,et al.  Cytochrome P450IIE1 genetic polymorphisms, racial variation, and lung cancer risk. , 1992, Cancer research.

[10]  P. Adamson,et al.  Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Janssen,et al.  Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo. , 1992, The Journal of pharmacology and experimental therapeutics.

[12]  R. Warrell,et al.  Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. , 1992, Cancer research.

[13]  E. Dmitrovsky,et al.  Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. , 1992, Blood.

[14]  Zi X. Chen,et al.  A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. , 1991, Blood.

[15]  D. Grant,et al.  Molecular mechanism of slow acetylation of drugs and carcinogens in humans. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[16]  E. Dmitrovsky,et al.  Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). , 1991, The New England journal of medicine.

[17]  F. Guengerich,et al.  Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. , 1991, Chemical research in toxicology.

[18]  J. A. Porter,et al.  The contribution of N‐hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects , 1990, Clinical pharmacology and therapeutics.

[19]  R Berger,et al.  All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. , 1990, Blood.

[20]  J. S. Miles,et al.  Identification of the primary gene defect at the cytochrome P450 CYP2D locus , 1990, Nature.

[21]  Zhen-yi Wang,et al.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. , 1988, Haematology and blood transfusion.

[22]  G. Van Nijen,et al.  Ketoconazole inhibits the in vitro and in vivo metabolism of all-trans-retinoic acid. , 1988, The Journal of pharmacology and experimental therapeutics.

[23]  R. Branch,et al.  Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. , 1987, Cancer research.

[24]  J. L. Napoli,et al.  Inhibition of retinoic acid metabolism by imidazole antimycotics in F9 embryonal carcinoma cells. , 1987, Biochemical pharmacology.

[25]  J. L. Napoli,et al.  Metabolism of retinoic acid and retinol during differentiation of F9 embryonal carcinoma cells. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[26]  G. Wilkinson,et al.  Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism , 1984, Clinical pharmacology and therapeutics.

[27]  C. Lieber,et al.  Retinoic acid metabolism by a system reconstituted with cytochrome P-450. , 1984, Archives of biochemistry and biophysics.

[28]  H. Koeffler.  Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications , 1983 .

[29]  C. Lieber,et al.  Increased metabolism of retinoic acid after chronic ethanol consumption in rat liver microsomes. , 1982, Archives of biochemistry and biophysics.

[30]  S. Collins,et al.  Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Sporn,et al.  Metabolism of all-trans-retinoic acid in hamster liver microsomes: oxidation of 4-hydroxy- to 4-keto-retinoic acid. , 1980, Archives of biochemistry and biophysics.

[32]  D. Trump.  Retinoids in bladder, testis and prostate cancer: epidemiologic, pre-clinical and clinical observations. , 1994, Leukemia.

[33]  J. Monbaliu,et al.  Effects of cytochrome P-450 inhibitors on the in vivo metabolism of all-trans-retinoic acid in rats. , 1990, The Journal of pharmacology and experimental therapeutics.

[34]  R. Branch,et al.  Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography. , 1984, Journal of chromatography.